JP2018538262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538262A5 JP2018538262A5 JP2018525598A JP2018525598A JP2018538262A5 JP 2018538262 A5 JP2018538262 A5 JP 2018538262A5 JP 2018525598 A JP2018525598 A JP 2018525598A JP 2018525598 A JP2018525598 A JP 2018525598A JP 2018538262 A5 JP2018538262 A5 JP 2018538262A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell binding
- binding domain
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims 88
- 210000001744 T-lymphocyte Anatomy 0.000 claims 59
- 206010028980 Neoplasm Diseases 0.000 claims 31
- 108091005804 Peptidases Proteins 0.000 claims 21
- 239000004365 Protease Substances 0.000 claims 21
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 230000008685 targeting Effects 0.000 claims 17
- 238000003776 cleavage reaction Methods 0.000 claims 16
- 230000007017 scission Effects 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078408A JP7525542B2 (ja) | 2015-11-19 | 2022-05-11 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| JP2024114909A JP2024138533A (ja) | 2015-11-19 | 2024-07-18 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257552P | 2015-11-19 | 2015-11-19 | |
| US62/257,552 | 2015-11-19 | ||
| US201562270907P | 2015-12-22 | 2015-12-22 | |
| US62/270,907 | 2015-12-22 | ||
| PCT/US2016/062748 WO2017087789A1 (en) | 2015-11-19 | 2016-11-18 | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078408A Division JP7525542B2 (ja) | 2015-11-19 | 2022-05-11 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538262A JP2018538262A (ja) | 2018-12-27 |
| JP2018538262A5 true JP2018538262A5 (enExample) | 2019-12-26 |
| JP7073258B2 JP7073258B2 (ja) | 2022-05-23 |
Family
ID=58717947
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525598A Active JP7073258B2 (ja) | 2015-11-19 | 2016-11-18 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| JP2022078408A Active JP7525542B2 (ja) | 2015-11-19 | 2022-05-11 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| JP2024114909A Pending JP2024138533A (ja) | 2015-11-19 | 2024-07-18 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078408A Active JP7525542B2 (ja) | 2015-11-19 | 2022-05-11 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| JP2024114909A Pending JP2024138533A (ja) | 2015-11-19 | 2024-07-18 | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10035856B2 (enExample) |
| EP (2) | EP3377103B2 (enExample) |
| JP (3) | JP7073258B2 (enExample) |
| CN (2) | CN112807429A (enExample) |
| AU (2) | AU2016358296B2 (enExample) |
| CA (1) | CA3003482A1 (enExample) |
| DK (1) | DK3377103T4 (enExample) |
| ES (1) | ES2873846T5 (enExample) |
| FI (1) | FI3377103T4 (enExample) |
| HU (1) | HUE054131T2 (enExample) |
| PL (1) | PL3377103T5 (enExample) |
| PT (1) | PT3377103T (enExample) |
| WO (1) | WO2017087789A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3932428A1 (en) | 2015-05-21 | 2022-01-05 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| JP7073258B2 (ja) | 2015-11-19 | 2022-05-23 | レビトープ リミテッド | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| AU2017229687A1 (en) * | 2016-03-08 | 2018-09-20 | Takeda Pharmaceutical Company Limited | Inducible binding proteins and methods of use |
| IL263102B2 (en) | 2016-05-20 | 2023-11-01 | Harpoon Therapeutics Inc | A serum albumin-binding protein with a single site |
| LT3461261T (lt) | 2016-05-20 | 2025-08-25 | Harpoon Therapeutics, Inc. | Vienos grandinės kintamo fragmento cd3 surišantys baltymai |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10849973B2 (en) | 2016-11-23 | 2020-12-01 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| KR20190087539A (ko) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | Psma 표적화 삼중특이성 단백질 및 사용 방법 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US20200115461A1 (en) * | 2017-05-03 | 2020-04-16 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
| US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
| KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020524710A (ja) | 2017-06-23 | 2020-08-20 | パソヴァックス エルエルシー | 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用 |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| AU2019271138A1 (en) | 2018-05-14 | 2021-01-07 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| KR20210028220A (ko) | 2018-07-02 | 2021-03-11 | 더 제너럴 하스피탈 코포레이션 | 항체 종양-표적화 조립 복합체 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2020131697A2 (en) * | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| SG11202106931PA (en) | 2018-12-27 | 2021-07-29 | Verimmune Llc | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors |
| JP2022524337A (ja) * | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 |
| US11685780B2 (en) | 2019-03-05 | 2023-06-27 | Takeda Pharmaceutical Company Limited | Single domain antigen binding domains that bind human Trop2 |
| US20220323600A1 (en) * | 2019-05-02 | 2022-10-13 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021168303A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| PE20230434A1 (es) * | 2020-07-10 | 2023-03-08 | Hoffmann La Roche | Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas |
| JP2023552040A (ja) | 2020-10-19 | 2023-12-14 | ヴェリミューン インコーポレイテッド | ウイルスにインスパイアされた組成物及びがんの治療のために同じものを使用して、既存の免疫応答をリダイレクトする方法 |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| KR20230131204A (ko) * | 2021-01-12 | 2023-09-12 | 에프. 호프만-라 로슈 아게 | 암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체 |
| EP4377347A1 (en) | 2021-07-27 | 2024-06-05 | MorphoSys AG | Combinations of antigen binding molecules |
| WO2025036892A1 (en) | 2023-08-14 | 2025-02-20 | Morphosys Ag | Cycat halfbody molecules comprising sterically occluding moieties |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3578568A (en) | 1968-11-29 | 1971-05-11 | Atlantic Richfield Co | Purification of low molecular weight epoxides by extractive distillation with a glycol or glycol ether |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0659438A1 (en) | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| AU5509296A (en) | 1995-05-03 | 1996-11-21 | Colin Henry Self | Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety |
| US20040197336A1 (en) | 1995-05-03 | 2004-10-07 | Self Colin Henry | Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety |
| EP2057999A3 (en) | 1995-12-22 | 2009-07-29 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| EP0926955A4 (en) | 1996-09-12 | 2003-05-07 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer |
| HRP970566A2 (en) | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
| GB9624993D0 (en) | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
| ATE383430T1 (de) | 1997-03-20 | 2008-01-15 | Us Gov Health & Human Serv | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren |
| JP2002510325A (ja) | 1997-07-10 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 前立腺癌の治療に有用なコンジュゲート |
| ES2207278T3 (es) | 1998-07-28 | 2004-05-16 | Micromet Ag | Heterominicuerpos. |
| EP1309705B1 (en) | 2000-07-25 | 2012-02-15 | Immunomedics Inc. | Multivalent target binding protein |
| AU2002223350A1 (en) | 2000-12-01 | 2002-06-11 | Eleanor N. Fish | Cytokine receptor binding peptides |
| JP2004524023A (ja) * | 2000-12-29 | 2004-08-12 | バイオ テクノロジー ジェネラル コーポレイション | 選択的癌療法のための特異的ヒト抗体 |
| AU2002345673B2 (en) * | 2001-06-13 | 2007-04-26 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CA2461351C (en) | 2001-09-26 | 2014-08-05 | Ira H. Pastan | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
| AU2002363861A1 (en) | 2001-11-30 | 2003-06-10 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| PT2357006E (pt) | 2002-07-31 | 2016-01-22 | Seattle Genetics Inc | Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa |
| CA2504818C (en) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| JP2007523602A (ja) | 2003-02-06 | 2007-08-23 | マイクロメット アクツィエン ゲゼルシャフト | 持続的なｔ細胞応答方法 |
| CN1812999A (zh) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | 包含EpCAM特异构建体的药物组合物 |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| SI1691833T1 (sl) | 2003-11-28 | 2010-06-30 | Micromet Ag | Zmes s polipeptidi |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US20050180979A1 (en) * | 2004-02-13 | 2005-08-18 | Micromet Ag | Anti-EpCAM immunoglobulins |
| GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| US20060045881A1 (en) | 2004-08-26 | 2006-03-02 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| EP1786469A2 (en) | 2004-09-10 | 2007-05-23 | Wyeth a Corporation of the State of Delaware | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| ATE530198T1 (de) | 2005-02-16 | 2011-11-15 | Univ Zuerich | Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist |
| US20090238822A1 (en) | 2005-10-13 | 2009-09-24 | Virexx Medical Corp. | Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response |
| US20100184651A1 (en) | 2005-11-18 | 2010-07-22 | Dabur Pharma Limited | Targeted fusion proteins for cancer therapy |
| US8623356B2 (en) | 2005-11-29 | 2014-01-07 | The University Of Sydney | Demibodies: dimerization-activated therapeutic agents |
| EP1981532A4 (en) | 2005-12-21 | 2010-06-30 | Medimmune Llc | EPHA2 MOLECULES AND USES THEREOF |
| GB0605702D0 (en) | 2006-03-21 | 2006-05-03 | Biotransformations Ltd | Materials and methods for immune cell stimulation |
| WO2008019366A2 (en) | 2006-08-07 | 2008-02-14 | Ludwig Institute For Cancer Research | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
| WO2008052322A1 (en) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers |
| WO2008063113A1 (en) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf |
| JP4866467B2 (ja) | 2007-01-30 | 2012-02-01 | エピバックス インコーポレーテッド | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| KR20090114430A (ko) | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신 |
| WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| GB0716160D0 (en) | 2007-08-17 | 2007-09-26 | Biotransformations Ltd | Materials and methods for treating cancers which express folate receptors |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| AU2010222929B2 (en) | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| ES2582603T5 (es) | 2008-10-01 | 2022-12-02 | Amgen Res Munich Gmbh | Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular |
| US20110178279A1 (en) | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| MX2012003175A (es) * | 2009-09-18 | 2012-04-11 | Micromet Ag | Regimen de dosificacion para administrar un anticuerpo bi-especifico epcamxcd3. |
| IN2012DN02692A (enExample) | 2009-11-05 | 2015-09-04 | Ct Molecular Med & Immunology | |
| US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
| EP2609111B1 (en) | 2010-08-24 | 2017-11-01 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising a disulfide stabilized-fv fragment |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| AU2012228100B2 (en) * | 2011-03-17 | 2016-09-08 | The University Of Birmingham | Re-directed immunotherapy |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| PE20141521A1 (es) * | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| SG11201403997SA (en) | 2012-01-13 | 2014-08-28 | Julius Maximilians Universität Würzburg | Dual antigen-induced bipartite functional complementation |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| TWI485161B (zh) * | 2012-03-02 | 2015-05-21 | Academia Sinica | 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 |
| JP2015516376A (ja) | 2012-03-19 | 2015-06-11 | ドイチェス クレブスフォルシュンクスツェントルム | Ｔ細胞エピトープを含む、ｂ細胞受容体複合体結合タンパク質 |
| IN2014MN02164A (enExample) | 2012-04-27 | 2015-08-28 | Cytomx Therapeutics Inc | |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| HK1210831A1 (en) | 2013-01-04 | 2016-05-06 | Cytomx Therapeutics Inc. | Compositions and methods for detecting protease activity in biological systems |
| HK1215262A1 (zh) | 2013-03-15 | 2016-08-19 | Bayer Healthcare Llc | 針對組織因子途徑抑制劑的前體藥物抗體 |
| UY35484A (es) * | 2013-03-15 | 2014-10-31 | Amgen Res Munich Gmbh | Molécula de unión de cadena simple que comprenden ABP de extremo N |
| KR20160018579A (ko) | 2013-06-04 | 2016-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항체를 접합하기 위한 조성물 및 방법 |
| GB201312133D0 (en) | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| RU2727836C2 (ru) | 2013-07-25 | 2020-07-24 | Сайтомкс Терапьютикс, Инк. | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения |
| CN118146306A (zh) | 2013-09-25 | 2024-06-07 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| CN105829349B (zh) * | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| JP6835586B2 (ja) | 2014-01-31 | 2021-02-24 | シトムクス セラピューティクス，インコーポレイティド | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| BR112017001579A2 (pt) | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos |
| CN104606127B (zh) * | 2015-01-21 | 2017-07-21 | 浙江峰盛生物工程有限公司 | 靶向egfr的载铂类药物白蛋白纳米粒及其制备与应用 |
| JP7073258B2 (ja) | 2015-11-19 | 2022-05-23 | レビトープ リミテッド | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| AU2017229687A1 (en) | 2016-03-08 | 2018-09-20 | Takeda Pharmaceutical Company Limited | Inducible binding proteins and methods of use |
| KR20210028220A (ko) * | 2018-07-02 | 2021-03-11 | 더 제너럴 하스피탈 코포레이션 | 항체 종양-표적화 조립 복합체 |
| WO2020131697A2 (en) * | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| US20220323600A1 (en) * | 2019-05-02 | 2022-10-13 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
-
2016
- 2016-11-18 JP JP2018525598A patent/JP7073258B2/ja active Active
- 2016-11-18 HU HUE16867215A patent/HUE054131T2/hu unknown
- 2016-11-18 WO PCT/US2016/062748 patent/WO2017087789A1/en not_active Ceased
- 2016-11-18 ES ES16867215T patent/ES2873846T5/es active Active
- 2016-11-18 FI FIEP16867215.2T patent/FI3377103T4/fi active
- 2016-11-18 DK DK16867215.2T patent/DK3377103T4/da active
- 2016-11-18 CN CN202110051430.6A patent/CN112807429A/zh active Pending
- 2016-11-18 CN CN201680065969.4A patent/CN108289952B/zh active Active
- 2016-11-18 US US15/355,511 patent/US10035856B2/en active Active
- 2016-11-18 EP EP16867215.2A patent/EP3377103B2/en active Active
- 2016-11-18 PT PT168672152T patent/PT3377103T/pt unknown
- 2016-11-18 AU AU2016358296A patent/AU2016358296B2/en active Active
- 2016-11-18 EP EP21150773.6A patent/EP3903818A1/en active Pending
- 2016-11-18 CA CA3003482A patent/CA3003482A1/en active Pending
- 2016-11-18 PL PL16867215.2T patent/PL3377103T5/pl unknown
-
2018
- 2018-06-28 US US16/021,777 patent/US20180346568A1/en active Pending
-
2020
- 2020-08-17 AU AU2020220048A patent/AU2020220048B2/en active Active
-
2022
- 2022-05-11 JP JP2022078408A patent/JP7525542B2/ja active Active
-
2024
- 2024-07-18 JP JP2024114909A patent/JP2024138533A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538262A5 (enExample) | ||
| FI3377103T4 (fi) | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten | |
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| NO20071788L (no) | Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav. | |
| MY206610A (en) | Antibodies binding to gprc5d | |
| WO2018098363A3 (en) | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| CY1118693T1 (el) | Αντισωματα αντι-ακτιβινης α και χρησεις αυτων | |
| JP2007516213A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| NO20083062L (no) | Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1 | |
| JP2013166763A5 (enExample) | ||
| HK1204557A1 (en) | Antigen binding proteins that bind pd-l1 | |
| NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
| WO2007005874A3 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
| WO2008047242A8 (en) | Novel anti-cd38 antibodies for the treatment of cancer | |
| JP2018505674A5 (enExample) | ||
| NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
| JP2019510733A5 (enExample) | ||
| JP2018509182A5 (enExample) | ||
| WO2011127412A3 (en) | Soluble human st-2 antibodies and assays | |
| WO2013054331A8 (en) | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) | |
| NZ731881A (en) | Anti-kit antibodies and uses thereof |